• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Elevation Oncology Inc.

    3/6/25 5:12:02 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELEV alert in real time by email
    S-8 1 tmb-20250306xs8.htm S-8

    As filed with the Securities and Exchange Commission on March 6, 2025

    Registration No. 333-

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    ​


    ​

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933


    ​

    ELEVATION ONCOLOGY, INC.

    (Exact name of registrant as specified in its charter)

    ​


    ​

    ​

    Delaware

        

    ​

        

    84-1771427

    (State or other jurisdiction of incorporation
    or organization)

     

    ​

     

    (I.R.S. Employer

    Identification Number)

    ​

    101 Federal Street, Suite 1900

    Boston, Massachusetts 02110

    (716) 371-1125

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

    ​

    2021 Equity Incentive Plan

    2021 Employee Stock Purchase Plan

    (Full title of the plan)

    ​

    Joseph J. Ferra, Jr.

    President and Chief Executive Officer

    Elevation Oncology, Inc.

    101 Federal Street, Suite 1900

    Boston, Massachusetts 02110

    (716) 371-1125

    (Name, address, including zip code, and telephone number, including area code, of agent for service)


    ​

    Copies to:

    ​

    Effie Toshav, Esq.

    Robert A. Freedman, Esq.

    Ryan Mitteness, Esq.

    Fenwick & West LLP

    401 Union Street

    Seattle, Washington 98101

    (206) 389-4510

    ​


    ​

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    ​

    Large accelerated filer  ☐

      

    Accelerated filer  ☐

      

    Non-accelerated filer  ⌧

      

    Smaller reporting company  ⌧

     

     

     

     

     

     

    Emerging growth company  ⌧

    ​

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

    ​

    ​

    ​

    ​


    REGISTRATION OF ADDITIONAL SHARES

    PURSUANT TO GENERAL INSTRUCTION E

    ​

    Elevation Oncology, Inc. (the “Registrant”) is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register (a) 2,956,557 additional shares of common stock available for issuance under the Registrant’s 2021 Equity Incentive Plan (“2021 EIP”), pursuant to the provision of the 2021 EIP providing for an automatic increase in the number of shares reserved for issuance thereunder on January 1 of each year equal to 5% of the number of issued and outstanding shares of common stock on December 31 of the immediately preceding year and (b) 591,311 additional shares of common stock available for issuance under the Registrant’s 2021 Employee Stock Purchase Plan (“2021 ESPP”), pursuant to the provision of the 2021 ESPP providing for an automatic increase in the number of shares reserved for issuance thereunder on January 1 of each year equal to 1% of the number of issued and outstanding shares of common stock on December 31 of the immediately preceding year.

    ​

    In accordance with General Instruction E of Form S-8, and only with respect to the common stock issuable under the 2021 EIP and 2021 ESPP, this Registration Statement hereby incorporates by reference the contents of the Registrant’s Registration Statements on Form S-8 filed with the Commission on June 25, 2021 (Registration No. 333-257377), March 3, 2022 (Registration No. 333-263250), March 9, 2023 (Registration No. 333-270386), and March 6, 2024 (Registration No. 333-277688), to the extent not superseded hereby.

    ​

    ​


    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference.

    The following documents filed by the Registrant with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”) are incorporated herein by reference:

    (a)

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 6, 2025 pursuant to Section 13 of the Exchange Act;

    (b)

    all other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

    (c)

    the description of the Registrant’s common stock contained in the Registrant’s registration statement on Form 8-A (File No. 001-40523) filed on June 21, 2021 under Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

    All documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing such documents, except as to specific sections of such documents as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement.

    ​


    Item 8.Exhibits.

    ​

    The following exhibits are filed herewith:

    ​

    ​

    ​

    Exhibit

    ​

    ​

    ​

    Incorporated by Reference

    ​

    Filed

    ​

    Number

        

    Exhibit Description

        

    Form

        

    File No.

        

    Exhibit

        

    Filing Date

        

    Herewith

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    3.1

    ​

    Restated Certificate of Incorporation, as amended

    ​

    10-K

    ​

    001-40523

    ​

    3.1

    ​

    3/6/2024

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    3.2

    ​

    Amended and Restated Bylaws

    ​

    8-K

    ​

    001-40523

    ​

    3.1

    ​

    3/3/2023

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    4.1

    ​

    Form of Common Stock Certificate

    ​

    S-1/A

    ​

    333-256787

    ​

    4.1

    ​

    6/21/2021

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    5.1

    ​

    Opinion of Fenwick & West LLP

    ​

    ​

    ​

    ​

    ​

    X

    ​

    ​

    ​

    ​

    ​

    ​

    23.1

    ​

    Consent of Fenwick & West LLP (contained in Exhibit 5.1)

    ​

    ​

    ​

    ​

    ​

    X

    ​

    ​

    ​

    ​

    ​

    ​

    23.2

    ​

    Consent of CohnReznick LLP, Independent Registered Public Accounting Firm

    ​

    ​

    ​

    ​

    ​

    X

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    24.1

    ​

    Power of Attorney (included on the signature page to this Registration Statement)

    ​

    ​

    ​

    ​

    ​

    X

    ​

    ​

    ​

    ​

    ​

    ​

    99.1

    ​

    2021 Equity Incentive Plan and forms of award agreements thereunder

    ​

    S-1/A

    ​

    333-256787

    ​

    10.3

    ​

    6/21/2021

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    99.2

    ​

    2021 Employee Stock Purchase Plan and forms of award agreements thereunder

    ​

    S-1/A

    ​

    333-256787

    ​

    10.4

    ​

    6/21/2021

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    107.1

    ​

    Filing Fee Table

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    X

    ​

    ​

    ​


    SIGNATURES

    ​

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on the 6th day of March, 2025.

    ​

     

    ELEVATION ONCOLOGY, INC.

     

     

     

     

    By:

    /s/ Joseph J. Ferra, Jr.

     

     

    Joseph J. Ferra, Jr.

     

     

    President and Chief Executive Officer

    ​

    POWER OF ATTORNEY

    ​

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Joseph J. Ferra, Jr. and Tammy Furlong, and each one of them, as his or her true and lawful attorney-in-fact, proxy and agent, with full power of substitution and resubstitution and full power to act without the other, for him or her in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact, proxies and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, proxies and agents, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    ​

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

    ​

    ​

    Name

        

    Title

        

    Date

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Joseph J. Ferra, Jr.

    ​

    President, Chief Executive Officer and Director

    ​

    March 6, 2025

    ​

    Joseph J. Ferra, Jr.

    ​

    (Principal Executive Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Tammy Furlong

    ​

    Chief Financial Officer

    ​

    March 6, 2025

    ​

    Tammy Furlong

    ​

    (Principal Financial and Accounting Officer)

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Steven A. Elms

    ​

    Chairman of the Board of Directors

    ​

    March 6, 2025

    ​

    Steven A. Elms

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ R. Michael Carruthers

    ​

    Director

    ​

    March 6, 2025

    ​

    R. Michael Carruthers

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Julie M. Cherrington, Ph.D.

    ​

    Director

    ​

    March 6, 2025

    ​

    Julie M. Cherrington, Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Timothy P. Clackson, Ph.D.

    ​

    Director

    ​

    March 6, 2025

    ​

    Timothy P. Clackson, Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Darcy Mootz, Ph.D.

    ​

    Director

    ​

    March 6, 2025

    ​

    Darcy Mootz, Ph.D.

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    ​

    /s/ Alan B. Sandler, M.D.

    ​

    Director

    ​

    March 6, 2025

    ​

    Alan B. Sandler, M.D.

    ​

    ​

    ​

    ​

    ​

    ​


    Get the next $ELEV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ELEV

    DatePrice TargetRatingAnalyst
    3/24/2025$5.00 → $1.00Overweight → Equal-Weight
    Stephens
    3/21/2025$1.00Outperform → Market Perform
    Leerink Partners
    3/21/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/21/2025$0.70Overweight → Neutral
    Piper Sandler
    1/3/2025Outperform
    William Blair
    5/31/2024$10.00Overweight
    Piper Sandler
    5/14/2024$8.00Overweight
    Stephens
    3/1/2024$7.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $ELEV
    SEC Filings

    View All

    SEC Form 15-12G filed by Elevation Oncology Inc.

    15-12G - Elevation Oncology, Inc. (0001783032) (Filer)

    8/4/25 4:34:55 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Elevation Oncology Inc.

    EFFECT - Elevation Oncology, Inc. (0001783032) (Filer)

    7/29/25 12:15:02 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Elevation Oncology Inc.

    EFFECT - Elevation Oncology, Inc. (0001783032) (Filer)

    7/29/25 12:15:05 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Elevation Oncology downgraded by Stephens with a new price target

    Stephens downgraded Elevation Oncology from Overweight to Equal-Weight and set a new price target of $1.00 from $5.00 previously

    3/24/25 8:34:27 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Elevation Oncology from Outperform to Market Perform and set a new price target of $1.00

    3/21/25 8:03:34 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology downgraded by Citizens JMP

    Citizens JMP downgraded Elevation Oncology from Mkt Outperform to Mkt Perform

    3/21/25 8:03:24 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sandler Alan B.

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:40:04 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Mootz Darcy

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:35:04 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Elms Steve

    4 - Elevation Oncology, Inc. (0001783032) (Issuer)

    7/24/25 4:30:06 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences for $0.36 in Cash per Share Plus a Contingent Value Right

    BOSTON, June 9, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ("Concentra"), whereby Concentra will acquire Elevation Oncology for $0.36 in cash per share of Elevation Oncology common stock ("Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 100% of the closing net cash in excess of $26.4 million; and (

    6/9/25 8:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates

    -- Presented preclinical data for potentially differentiated HER3 ADC, EO-1022, at AACR Annual Meeting -- -- Expects to file IND application for EO-1022 in 2026 -- -- Cash runway into 2H 2026 -- BOSTON, May 15, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2025, and provided recent business updates. "We recently presented preclinical proof-of-concept data for EO-1022, reaffirming its potential as a differentiated HER3 ADC, an

    5/15/25 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Presents Preclinical Proof-of-Concept Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

    -- EO-1022 is a potentially differentiated HER3 ADC designed to address significant unmet needs across multiple solid tumors -- -- On-track to file IND application in 2026 -- BOSTON, April 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical proof-of-concept data for its novel HER3 antibody-drug conjugate (ADC), EO-1022. The data will be presented in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, b

    4/25/25 1:00:00 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:50:19 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 7:05:59 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Elevation Oncology Inc.

    SC 13G/A - Elevation Oncology, Inc. (0001783032) (Subject)

    11/14/24 6:45:37 PM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Leadership Updates

    Live Leadership Updates

    View All

    Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors

    BOSTON, March 4, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointments of Julie Cherrington, Ph.D. and Alan Sandler, M.D., to its Board of Directors. "We are thrilled to welcome Julie and Alan as Elevation Oncology's newest directors," said Steve Elms, Chairman of Elevation Oncology. "Both are extremely experienced drug developers, who have contributed to the advancement and approval of multiple targeted therapies for the treatment of cancer. On behalf of the Board,

    3/4/24 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors

    BOSTON, Jan. 22, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the appointment of Darcy Mootz, Ph.D., to its Board of Directors. Dr. Mootz is an experienced life sciences executive, who brings expertise across corporate strategy, corporate development, finance, and operations to Elevation Oncology's Board of Directors. "We are pleased to welcome Darcy to the Elevation Oncology board, as she is a uniquely qualified leader, who has experience crafting late-stage development str

    1/22/24 7:30:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Appoints Joseph Ferra as Chief Executive Officer and Promotes Tammy Furlong to Chief Financial Officer

    NEW YORK, July 13, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, announced today the appointment of Joseph Ferra, M.B.A., as its Chief Executive Officer. Mr. Ferra was previously Interim Chief Executive Officer and Chief Financial Officer. Mr. Ferra will also join the Elevation Oncology Board of Directors. In addition, the Company announced the appointment of Tammy Furlong, M.B.A., C.P.A., as Chief Financial Officer, promoted from her previous role as Vice President of Finance and Accounting

    7/13/23 8:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ELEV
    Financials

    Live finance-specific insights

    View All

    Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements

    -- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30

    8/6/24 7:10:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2

    -- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer ---- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/hypoesthesia --  -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 ---- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 ---- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON, Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective ca

    8/6/24 7:00:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Elevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical Group

    Obtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801)Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including those with Claudin18.2 overexpressionCompany expects to initiate a Phase 1 clinical trial in the U.S. evaluating EO-3021 (SYSA1801) in 2023Management to host an investor conference call and webcast today at 5:00 p.m. ET NEW YORK, July 28, 2022 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), a clinical stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, tod

    7/28/22 8:45:00 AM ET
    $ELEV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care